AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32020130
Drug: L-PRF application
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-PRF application after surgical removal of impacted third molar
Trial: 35018760
Drug: Thiamazole treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamazole treatment for 5-8 months
Trial: 35018760
Drug: Thiamazole treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamazole treatment for 9-12 months
Trial: 35018760
Drug: Thiamazole treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamazole treatment for more than 12 months
Trial: 36314172
Drug: Tegoprazan 25
RxNorm normalized name: Tegoprazan
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan 25 mg
Trial: 33123304
Drug: Brief acceptance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief acceptance and commitment therapy (individual condition)
Trial: 33123304
Drug: Brief acceptance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief acceptance and commitment therapy (group condition)
Trial: 34620199
Drug: Time-restricted feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-restricted feeding (10-h restricted feeding treatment program; ad libitum feeding from 8:00 to 18:00 h; fasting between 18:00 and 8:00 h) for 12 weeks
Trial: 35078268
Drug: OnabotulinumtoxinA (OBTX‐A)
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA (OBTX‐A) injection
Trial: 33651384
Drug: Progressive muscle
RxNorm normalized name: ActivOn Joint & Muscle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progressive muscle relaxation exercises performed twice a day for 5 days
Trial: 35388776
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy (ICBT) for 5 weeks
Trial: 35388776
Drug: Group-based face-to-face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based face-to-face cognitive-behavioral therapy (CBT)
Trial: 32710787
Drug: 15N-labeled milk
RxNorm normalized name: Milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15N-labeled milk protein concentrate (25 g - low protein)
Trial: 32710787
Drug: 15N-labeled milk
RxNorm normalized name: Milk
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15N-labeled milk protein concentrate (50 g - high protein)
Trial: 33066723
Drug: Ecopipam (25–100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam (25–100 mg/day)
Trial: 34836058
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of CMR (3% - 750 mg)
Trial: 34836058
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of CMR (2% - 500 mg)
Trial: 34836058
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of CMR (1% - 250 mg)
Trial: 32139384
Drug: Metformin increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin increased by ≥1,000 mg/day
Trial: 32139384
Drug: Metformin unchanged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin unchanged
Trial: 32139384
Drug: Metformin decreased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin decreased
Trial: 33581721
Drug: ANI-guided group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANI-guided group (loading dose of 75 μg of fentanyl followed by 25 μg when ANI score was under 50)
Trial: 33581721
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same loading dose followed by 25 μg every 30 min with additional doses for inadequate analgesia)
Trial: 32269181
Drug: 0.066 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.066 mg/kg/day GH
Trial: 32269181
Drug: 0.033 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.033 mg/kg/day GH
Trial: 34933316
Drug: Povidone-iodine in
RxNorm normalized name: povidone-iodine Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine in aqueous solution
Trial: 32990206
Drug: Combination sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination sedation (propofol with midazolam, fentanyl, dexmedetomidine, and/or ketamine)
Trial: 35690060
Drug: e‐cigarettes with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: e‐cigarettes with 30 mg/g nicotine in e‐liquid
Trial: 33872982
Drug: Prolgolimab 1
RxNorm normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolgolimab 1 mg/kg every 2 weeks (arm 1)
Trial: 33872982
Drug: Prolgolimab 3
RxNorm normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolgolimab 3 mg/kg every 3 weeks (arm 2)
Trial: 34588237
Drug: Ad26.ZEBOV (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV (first dose)
Trial: 34588237
Drug: MVA‐BN‐Filo (second
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MVA‐BN‐Filo (second dose)
Trial: 34588237
Drug: Ad26.ZEBOV (booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV (booster dose)
Trial: 34588237
Drug: Ad26.ZEBOV (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ad26.ZEBOV (first dose) to Ad26.ZEBOV (booster dose)
Trial: 36428044
Drug: Solution-focused approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused approach (7-session program of anger management and prevention of violent behavior)
Trial: 36380971
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg tablets daily for four weeks
Trial: 36380971
Drug: Clarithromycin 500
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 500 mg tablets twice daily for four weeks
Trial: 35766956
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg for bolus over 10 min before induction of anesthesia, 1.5 mg/kg/h for continuous infusion)
Trial: 35766956
Drug: Dexmedetomidine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (0.5 µg/kg for bolus over 10 min before induction of anesthesia, 0.4 µg/kg/h for continuous infusion)
Trial: 35766956
Drug: Lidocaine plus
RxNorm normalized name: Icy Hot Lidocaine Plus Menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine plus Dexmedetomidine (Lidocaine: 1.5 mg/kg for bolus over 10 min before induction of anesthesia, 1.5 mg/kg/h for continuous infusion; Dexmedetomidine: 0.5 µg/kg for bolus over 10 min before induction of anesthesia, 0.4 µg/kg/h for continuous infusion)
Trial: 33833179
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (propofol infusion without vibration analgesia)
Trial: 32997437
Drug: Oscillatory positive
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oscillatory positive expiratory pressure therapy (OPEPT)
Trial: 35190420
Drug: 'Is insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 'Is insulin right for me?' (intervention)
Trial: 32691639
Drug: Dichrostachys glomerata
RxNorm normalized name: Dichrostachys cinerea whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dichrostachys glomerata (DG; 300 mg/d)
Trial: 35704218
Drug: Intravenous calcium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous calcium gluconate (IV) 10% (n = 30)
Trial: 35704218
Drug: Oral elemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral elemental calcium (n = 30)
Trial: 35704218
Drug: Intravenous calcium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous calcium gluconate (IV) 10%
Trial: 35704218
Drug: Oral elemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral elemental calcium
Trial: 33455112
Drug: FLOT neoadjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT neoadjuvant chemotherapy with omega 3
Trial: 33455112
Drug: FLOT chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLOT chemotherapy alone
Trial: 32453377
Drug: Viltolarsen 40
RxNorm normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Viltolarsen 40 mg/kg per week
Trial: 32453377
Drug: Viltolarsen 80
RxNorm normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Viltolarsen 80 mg/kg per week
Trial: 35108294
Drug: Attention-control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-control condition (same dose as intervention but focused on nutrition, physical activity, and weight stigma)
Trial: 35529427
Drug: Platelet-Rich Plasma
RxNorm normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-Rich Plasma (PRP) and Adipose-Derived Mesenchymal Stem Cells (AD-MSCs) injection
Trial: 35860417
Drug: Amitriptyline (medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (medication group)
Trial: 35132039
Drug: Intensive blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive blood pressure treatment targeting SBP of less than 120 mmHg
Trial: 35132039
Drug: Standard blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard blood pressure treatment targeting SBP of less than 140 mmHg
Trial: 33873028
Drug: Treatment-Control (TCC)
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-Control (TCC)
Trial: 34653660
Drug: Melatonin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (10 mg in addition to standard therapeutic care)
Trial: 34407343
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg atogepant
Trial: 34407343
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg atogepant
Trial: 34407343
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg atogepant
Trial: 33037961
Drug: Group Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Cognitive Behavioural Therapy (GCBT) for 8 weeks
Trial: 35094848
Drug: fevipiprant 150
RxNorm normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fevipiprant 150 mg
Trial: 35094848
Drug: fevipiprant 450
RxNorm normalized name: Fevipiprant
DrugBank: Fevipiprant (DB12011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fevipiprant 450 mg
Trial: 32297992
Drug: Topiramate 100
RxNorm normalized name: topiramate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 100 mg
Trial: 32297992
Drug: Topiramate 150
RxNorm normalized name: topiramate 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate 150 mg
Trial: 32006699
Drug: Levorphanol (potent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levorphanol (potent opioid), average final daily dose 132 mg (range 14 to 300 mg), with 5 weeks titration followed by 20 weeks stable dosing.
Trial: 34018365
Drug: Hyperin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperin treatment at 75 mg/(kg·d) for 4 weeks
Trial: 34018365
Drug: POI model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: POI model group (TG at 40 mg/kg twice a day for 2 weeks)
Trial: 32714989
Drug: Jaques-Dalcroze Eurhythmics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jaques-Dalcroze Eurhythmics exercise programme (12 weeks, twice a week for 45 minutes)
Trial: 33252564
Drug: Ophthalmic Viscosurgical
RxNorm normalized name: Viscoat Ophthalmic Viscosurgical Device Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ophthalmic Viscosurgical Device (OVD)
Trial: 33441705
Drug: I3 (100%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I3 (100% of crop's water requirement, non-stress treatment)
Trial: 35917364
Drug: Single-dose mebendazole
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-dose mebendazole
Trial: 35595817
Drug: Sequential paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sequential paclitaxel treatment followed by fluorinated‐pyrimidine‐based adjuvant chemotherapy
Trial: 35595817
Drug: Monotherapy (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (not explicitly named in the abstract)
Trial: 35637324
Drug: Prescription-grade Crystalline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription-grade Crystalline Glucosamine Sulfate (pCGS) 1500 mg/day
Trial: 34218304
Drug: Rupatadine (RUP)
RxNorm normalized name: rupatadine
DrugBank: Rupatadine (DB11614)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Rupatadine (RUP) 10 mg once daily
Trial: 34218304
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 15–25 mg/week plus placebo
Trial: 34234406
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NSAID and steroid eye drops (group A)
Trial: 34234406
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of NSAID and steroid eye drops (groups A and B)
Trial: 32485438
Drug: Citrate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrate dose
Trial: 32070122
Drug: Group-based music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based music intervention (n=26), delivered twice weekly for 12 weeks
Trial: 34048281
Drug: Large dose
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large dose of shoulder strengthening added to usual nonoperative care
Trial: 35639159
Drug: l-ERBT
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-ERBT
Trial: 32539815
Drug: Chemotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy with c-KIT mutation
Trial: 33766992
Drug: IV immunoglobulin
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV immunoglobulin (IVIG) 2 g/kg body weight followed by 3 additional infusions of 1 g/kg at 3-week intervals
Trial: 34817561
Drug: Sleep Education
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep Education Therapy (SET)
Trial: 34817561
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) with sustained remission of insomnia disorder
Trial: 34556520
Drug: Intranasal oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU, 48 IU)
Trial: 35695687
Drug: Kovir capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kovir capsule
Trial: 33407792
Drug: Pulmonary rehabilitation
RxNorm normalized name: Lobaria pulmonaria extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary rehabilitation program (supervised, outpatient, twice weekly for 8 weeks)
Trial: 34022445
Drug: Extraperitoneal laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraperitoneal laparoscopic group (X-L)
Trial: 34022445
Drug: Transperitoneal laparoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transperitoneal laparoscopic group (T-L)
Trial: 33080934
Drug: 1 cup
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cup Red Raspberry (RRB) with 8 g Fructo-Oligosaccharides (FOS) per day for 4 weeks
Trial: 35916800
Drug: Omega-3 (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 (1,000 mg daily for 10 months)
Trial: 35916800
Drug: Vitamin-D (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-D (1.5 mL daily for 10 months)
Trial: 35916800
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (hydroxyurea + Ibuprofen)
Trial: 32679209
Drug: Intralymphatic allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic allergen immunotherapy (ILIT) with 3 injections and a booster 1 year later
Trial: 32679209
Drug: Intralymphatic allergen
RxNorm normalized name: catfish allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralymphatic allergen immunotherapy (ILIT)
Trial: 35346165
Drug: eGFR <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR < 60 mL/min/1.73 m²
Trial: 36482103
Drug: Atezolizumab plus
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab plus pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide (atezo-chemo)
Trial: 36482103
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus pegylated liposomal doxorubicin (PLD) and low-dose cyclophosphamide (placebo-chemo)
Trial: 33694229
Drug: Rectal bacteriotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal bacteriotherapy
Trial: 34989174
Drug: NPC-21 1
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-21 1 mg/kg
Trial: 34989174
Drug: NPC-21 3
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-21 3 mg/kg
Trial: 34989174
Drug: NPC-21 10
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-21 10 mg/kg
Trial: 34989174
Drug: NPC-21 20
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-21 20 mg/kg
Trial: 34858513
Drug: Ashwagandha SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashwagandha SR (300 mg)
Trial: 32538005
Drug: Balance acupuncture
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance acupuncture therapy combined with exercise re-learning rehabilitation therapy
Trial: 34591105
Drug: AstraZeneca vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AstraZeneca vaccine with information on effectiveness at preventing death from COVID-19
Trial: 34591105
Drug: AstraZeneca vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AstraZeneca vaccine with information on overall effectiveness at preventing symptomatic transmission
Trial: 34591105
Drug: Johnson &
RxNorm normalized name: Johnson & Johnson Eye Sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Johnson & Johnson vaccine with information on effectiveness at preventing death from COVID-19
Trial: 34591105
Drug: Johnson &
RxNorm normalized name: Johnson & Johnson Eye Sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Johnson & Johnson vaccine with information on overall efficacy at preventing symptomatic infection
Trial: 32062728
Drug: Individualized antipsychotic
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized antipsychotic dose reduction
Trial: 32062728
Drug: Continuous maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous maintenance treatment
Trial: 33403878
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (healthy subjects with RF concentration <11.1 IU/mL)
Trial: 32749561
Drug: Association of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Association of mechanical brushing with oral irrigation (WP)
Trial: 35859328
Drug: Control (rhG-CSF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (rhG-CSF when WBC < 2.0 × 10^9/L or ANC < 1.0 × 10^9/L)
Trial: 36470777
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation training (including digital operating system training, music therapy, aerobic training, and mental health intervention) for 6 months
Trial: 35572853
Drug: LT3 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LT3 monotherapy
Trial: 32584065
Drug: Randomized planned
RxNorm normalized name: jojoba oil, randomized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized planned missingness design in daily diary study
Trial: 34979943
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous analgesia (PIA)
Trial: 32836220
Drug: Aflibercept treatment
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept treatment (1 dose)